Cochrane · systematic review · CD003376
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
Wells, GA, Hsieh, S-C, Peterson, J, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 5 · 41.7%Low 3 · 25%Moderate 2 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intermittent/cyclic etidronate 400 mg/day compared to placebo for the primary prevention of osteoporotic fractures in postmenopausal women
Population: postmenopausal women with a lower risk for fracturesa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical vertebral fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 3.03 [0.32, 28.44] | NR | Low Downgraded: imprecision |
Non‐vertebral fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 0.56 [0.2, 1.61] | NR | Moderate Downgraded: imprecision |
Hip fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision |
Wrist fractures № of participants: 0 (0 RCTs) Intermittent/cyclic etidronate 400 mg/day vs placebo | no estimate extracted | NR | No studies |
Withdrawals due to adverse events Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 1.41 [0.81, 2.47] | NR | Low Downgraded: risk of bias, imprecision |
Serious adverse events Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 0.9 [0.52, 1.54] | NR | Moderate Downgraded: risk of bias, imprecision |
Intermittent/cyclic etidronate 400 mg/day compared to placebo for the secondary prevention of osteoporotic fractures in postmenopausal women
Population: postmenopausal women with a higher risk for fracturesa
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical vertebral fractures № of participants: 0 (0 RCTs) Intermittent/cyclic etidronate 400 mg/day vs placebo | no estimate extracted | NR | No studies |
Non‐vertebral fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 1.07 [0.72, 1.58] | NR | Low Downgraded: risk of bias, imprecision, indirectness |
Hip fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 0.93 [0.17, 5.19] | NR | Very low Downgraded: risk of bias, imprecision, indirectness |
Wrist fractures Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 0.9 [0.13, 6.04] | NR | Very low Downgraded: risk of bias, imprecision, indirectness |
Withdrawals due to adverse events Intermittent/cyclic etidronate 400 mg/day vs placebo | RR 1.09 [0.54, 2.18] | NR | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Intermittent/cyclic etidronate 400 mg/day vs placebo | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision, indirectness |